loading
loading
Hospital stocks including Fortis Healthcare, Dr Agarwal’s, Manipal, Apollo Hospitals and Medanta extended their losses for a second straight session on Thursday, after falling as much as 10% in the previous session, as the Supreme Court questioned steep markups on cancer drugs and asked the government to examine allegations that hospitals require patients to purchase medicines from their own or designated pharmacies. However, Jefferies sees this as an excellent entry point to buy these 6 stocks. Jefferies has a Buy rating on Apollo Hospitals with a target price of Rs 10,350, implying 27% upside, while its FY26E-29E EBITDA CAGR is estimated at 20%. Jefferies has a Buy rating on Dr Agarwal’s Healthcare with a target price of Rs 600, implying 25% upside, while its FY26E-29E EBITDA CAGR is estimated at 23%. Jefferies has a Buy rating on Fortis Healthcare with a target price of Rs 1,125, implying 46% upside, while its FY26E-29E EBITDA CAGR is estimated at 17%. Jefferies has a Buy rating on Max Healthcare with a target price of Rs 1,260, implying 36% upside, while its FY26E-29E EBITDA CAGR is estimated at 18%. Jefferies has a Buy rating on Manipal Health Enterprises with a target price of Rs 870, implying 23% upside, while its FY26E-29E EBITDA CAGR is estimated at 19%. Jefferies has a Buy rating on Medanta with a target price of Rs 1,660, implying 22% upside, while its FY26E-29E EBITDA CAGR is estimated at 22%. Disclaimer: This article has been written by Veer Sharma, who is not a SEBI-registered Research Analyst or an Investment Adviser. Veer Sharma and his ‘relative(s)’ (as defined under Section 2(77) of the Companies Act, 2013) do not hold any financial interest in the companies mentioned in this article as of the date of publication. The views/recommendations mentioned in this article, wherever applicable, are those of the respective SEBI-registered Research Analyst/brokerage and have been reproduced/reported with due attribution. They should not be construed as the views or recommendations of The Economic Times Digital or the journalist. Readers are advised to consider the original research report and make their investment decisions based on their own assessment. Brokerage disclaimers here.
document fetched 2026-10-03 02:56